Could intratumoural microbiota be key to unlocking treatment responses in hepatocellular carcinoma? DOI Creative Commons

Kin Lam Yu,

Sj Shen

European Journal of Cancer, Journal Year: 2024, Volume and Issue: 216, P. 115195 - 115195

Published: Dec. 21, 2024

Hepatocellular carcinoma (HCC) is the third cause of cancer-related mortality worldwide. Current treatments include surgery and immunotherapy with variable response. Despite aggressive treatment, disease progression remains biggest contributor to mortality. Thus, there an urgent unmet need improve current through a better understanding HCC tumourigenesis. The gut microbiota has been intensively examined in context HCC, evidence showing modulation potential modulate tumourigenesis prognosis. In addition, recent literature suggests presence intratumoural that may exert significant impacts on development solid tumours including HCC. By drawing parallels between hepatic/tumoural microbiota, we explore present review how hepatic established, its impact tumourigenesis, be key improving particular, highlight bacteria have discovered tumours, they affect tumour immune microenvironment We then therapies target microbiota. With deeper different involved can targeted, hope spark future research validating as avenue for treatment responses

Language: Английский

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial DOI Creative Commons
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(4), P. 807 - 823

Published: July 23, 2024

Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, lack predictive biomarkers and limited understanding response mechanisms remain a challenge. Using data from IMbrave150plus cohort, we applied an immune signature score (ISS) predictor to stratify HCC patients treated with bevacizumab or sorafenib alone into potential high low groups. By applying multiple statistical approaches including Bayesian covariate prediction algorithm, refined 10 key genes (ISS10) clinical use while maintaining similar power full model. We further validated ISS10 in independent cohort nivolumab ipilimumab. The study identified significant association between ISS treatment response. Among classified as responders, those combination exhibited improved overall progression-free survival well better objective rate compared sorafenib. also observed correlation ipilimumab treatment. Analysis cell subpopulations revealed distinct characteristics associated subtypes. In particular, subtype displayed more favorable environment higher proportions antitumor macrophages activated T-cells, potentially explaining its Our suggests that are promising enhanced therapeutic outcomes undergoing immunotherapy. These markers crucial refining patient stratification personalized advance effectiveness standard-of-care regimens.

Language: Английский

Citations

4
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches DOI Open Access
Shabnam Eghbali, Thatcher Heumann

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 236 - 236

Published: Jan. 13, 2025

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and, with only 15-20% HCC patients being suitable for potentially curative treatments, the vast majority ultimately require systemic therapy. For decades, choice effective therapy remained sparse. In recent years, after combination atezolizumab and bevacizumab demonstrated superior overall survival over first-line standard, sorafenib, there has been major therapeutic paradigm shift to immunotherapy-based regimens HCC. While representing great leap forward treatment this cancer, reality that less than one-third achieve an objective response immune checkpoint inhibitor-based therapy, so remains significant clinical need further optimization. review, we provide overview current landscape immunotherapy unresectable delve into tumor intrinsic extrinsic mechanisms resistance established immunotherapies focus on novel targets strong translational potential. Following this, spotlight emerging approaches notable trials aiming optimize efficacy in include inhibitors, microenvironment modulators, targeted delivery systems, locoregional interventions.

Language: Английский

Citations

0
Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma DOI
Mathew Vithayathil,

Deniz Koku,

Claudia Campani

et al.

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue? DOI
Charalampos Theocharopoulos, Ioannis A. Ziogas,

Charalampos-Christos Douligeris

et al.

Cancer Treatment Reviews, Journal Year: 2024, Volume and Issue: 129, P. 102806 - 102806

Published: July 29, 2024

Language: Английский

Citations

1
Could intratumoural microbiota be key to unlocking treatment responses in hepatocellular carcinoma? DOI Creative Commons

Kin Lam Yu,

Sj Shen

European Journal of Cancer, Journal Year: 2024, Volume and Issue: 216, P. 115195 - 115195

Published: Dec. 21, 2024

Hepatocellular carcinoma (HCC) is the third cause of cancer-related mortality worldwide. Current treatments include surgery and immunotherapy with variable response. Despite aggressive treatment, disease progression remains biggest contributor to mortality. Thus, there an urgent unmet need improve current through a better understanding HCC tumourigenesis. The gut microbiota has been intensively examined in context HCC, evidence showing modulation potential modulate tumourigenesis prognosis. In addition, recent literature suggests presence intratumoural that may exert significant impacts on development solid tumours including HCC. By drawing parallels between hepatic/tumoural microbiota, we explore present review how hepatic established, its impact tumourigenesis, be key improving particular, highlight bacteria have discovered tumours, they affect tumour immune microenvironment We then therapies target microbiota. With deeper different involved can targeted, hope spark future research validating as avenue for treatment responses

Language: Английский

Citations

0